Comparative cost analysis of management of secondary hyperparathyroidism with paricalcitol or cinacalcet with low-dose vitamin D in hemodialysis patients

References

• CDC. National Chronic Kidney Disease Fact Sheet: general information and national estimates on chronic kidney disease in the United States, 2010. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2010
   Google Scholar
• Zhang Q-L, Rothenbacher D. Prevalence of chronic kidney disease in population-based studies: Systematic review. BMC Public Health 2008;8:117
   PubMed Web of Science ®Google Scholar
• Barsoum RS. Chronic kidney disease in the developing world. N Engl J Med 2006;354:997-9
   PubMed Web of Science ®Google Scholar
• Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA 2007;298:2038-47
   PubMed Web of Science ®Google Scholar
• Haroun MK, Jaar BG, Hoffman SC, et al. Risk factors for chronic kidney disease: a prospective study of 23,534 men and women in Washington County, Maryland. J Am Soc Nephrol 2003;14:2934-41
   PubMed Web of Science ®Google Scholar
• Rix M, Andreassen H, Eskildsen P, et al. Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failure. Kidney Int 1999;56:1084-93
   PubMed Web of Science ®Google Scholar
• Coco M, Rush H. Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis 2000;36:1115-21
   PubMed Web of Science ®Google Scholar
• Tsuchihashi K, Takizawa H, Torii T, et al. Hypoparathyroidism potentiates cardiovascular complications through disturbed calcium metabolism: possible risk of vitamin D(3) analog administration in dialysis patients with end-stage renal disease. Nephron 2000;84:13-20
   PubMed Web of Science ®Google Scholar
• Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296-305
   PubMed Web of Science ®Google Scholar
• Weiner DE, Tighiouart H, Stark PC, et al. Kidney disease as a risk factor for recurrent cardiovascular disease and mortality. Am J Kidney Dis 2004;44:198-206
   PubMed Web of Science ®Google Scholar
• Slinin Y, Foley RN, Collins AJ. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study. J Am Soc Nephrol 2005;16:1788-93
   PubMed Web of Science ®Google Scholar
• National Kidney Foundation. KDOQI Clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42:S1-S202
   PubMed Web of Science ®Google Scholar
• National Kidney Foundation. KDIGO Clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD–MBD). Chapter 4.1: treatment of CKD-MBD targeted at lowering high serum phosphorus and maintaining serum calcium. Kidney Int 2009;76:S50-S99
   Google Scholar
• Teng M, Wolf M, Lowrie E, et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003;349:446-56
   PubMed Web of Science ®Google Scholar
• Dobrez DG, Mathes A, Amdahl M, et al. Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings. Nephrol Dial Transplant 2004;19:1174-81
   PubMed Web of Science ®Google Scholar
• Sprague SM, Llach F, Amdahl M, et al. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 2003;63:1483-90
   PubMed Web of Science ®Google Scholar
• Coyne DW, Grieff M, Ahya SN, et al. Differential effects of acute administration of 19-Nor-1,25-dihydroxy-vitamin D2 and 1,25-dihydroxy-vitamin D3 on serum calcium and phosphorus in hemodialysis patients. Am J Kidney Dis 2002;40:1283-8
   PubMed Web of Science ®Google Scholar
• Joist HE, Ahya SN, Giles K, et al. Differential effects of very high doses of doxercalciferol and paricalcitol on serum phosphorus in hemodialysis patients. Clin Nephrol 2006;65:335-41
   PubMed Web of Science ®Google Scholar
• Rosery H, Bergemann R, Marx SE, et al. Health-economic comparison of paricalcitol, calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism during haemodialysis. Clin Drug Investig 2006;26:629-38
   Google Scholar
• Hansen D, Rasmussen K, Danielsen H, et al. No difference between alfacalcidol and paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients: a randomized crossover trial. Kidney Int 2011;80:841-50
   PubMed Web of Science ®Google Scholar
• Block GA, Martin KJ, de Francisco AL, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004;350:1516-25
   PubMed Web of Science ®Google Scholar
• Block GA, Zaun D, Smits G, et al. Cinacalcet hydrochloride treatment significantly improves all-cause and cardiovascular survival in a large cohort of hemodialysis patients. Kidney Int 2010;78:578-89
   PubMed Web of Science ®Google Scholar
• Fishbane S, Shapiro WB, Corry DB, et al. Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results. Clin J Am Soc Nephrol 2008;3:1718-25
   PubMed Web of Science ®Google Scholar
• Ketteler M, Martin KJ, Wolf M, et al. Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study. Nephrol Dial Transplant 2012;27:3270-8
   PubMed Web of Science ®Google Scholar
• Ketteler M, Martin KJ, Cozzolino M, et al. Paricalcitol versus cinacalcet plus low-dose vitamin D for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: study design and baseline characteristics of the IMPACT SHPT study. Nephrol Dial Transplant 2012;27:1942-9
   PubMed Web of Science ®Google Scholar
• Ross EA, Tian J, Abboud H, et al. Oral paricalitol for treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis. Am J Nephrol 2008;28:97-106
   PubMed Web of Science ®Google Scholar
• Llach F, Yudd M. Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism. Am J Kidney Dis 2001;38(5 Suppl):S45-50
   Web of Science ®Google Scholar
• Shireman TI, Almehmi A, Wetmore JB, et al. Economic analysis of cinacalcet in combination with low-dose vitamin D versus flexible-dose vitamin D in treating secondary hyperparathyroidism in hemodialysis patients. Am J Kidney Dis 2010;56:1108-16
   Google Scholar
• Sprague SM, Evenepoel P, Curzi M, et al. Simultaneous control of PTH and CaxP is sustained over three years of treatment with cinacalcet HCl. Clin J Am Soc Nephro 2009;4:1465-76
   PubMed Web of Science ®Google Scholar
• Schumock GT, Walton SM, Lee TA, et al. Comparative effectiveness of paricalcitol versus cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. Nephron Clin Pract 2011;117:c151-9
   Google Scholar